Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHAD) is a rare genetic disorder that belongs to a group of diseases associated with impaired oxidative metabolism of fatty acids. This defect causes accumulation of long-chain acyl-CoA derivatives, which leads to various symptoms, including myopathy, heart failure, and metabolic crisis. The basis of the pathology is insufficient activity of the enzyme 3-hydroxyacyl-CoA dehydrogenase, which plays a key role in the oxidative metabolism of long-chain fatty acids necessary for the normal functioning of cells and tissues. LCHAD deficiency can manifest itself early in life and requires early diagnosis and treatment to prevent serious complications and improve the quality of life of patients.
History of the disease and interesting historical facts
Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency was first described in 1986. Research showed that the disorder was recessive in nature, which determined its study in the following decades. The advent of molecular genetics in the 1990s opened up new horizons for diagnosis and understanding of the disease mechanism. Since then, significant strides have been made in understanding the genetic basis of LCHAD, identifying the various mutations responsible for the development of this condition. Historically, this was an important moment in pediatrics and biochemistry, as it demonstrated the need for newborn screening for the timely diagnosis of metabolic diseases.
Epidemiology
The distribution of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency varies by population and geographic location. In the general population, its incidence is estimated to be approximately 1 in 50,000 births. However, in some highly inbred populations (e.g., populations in parts of Europe and the Middle East), the incidence may be as high as 1 in 20,000. In addition, more than 100 cases of the disease are known to have been reported, suggesting that it is a relatively important rare inherited disorder.
Genetic predisposition to this disease
LCHAD deficiency is caused by mutations in the HADHA gene, located on chromosome 2 (2p23.3). This gene encodes the alpha subunit of a mitochondrial enzyme required for the oxidative metabolism of long-chain fatty acids. More than 30 known mutations in HADHA can lead to the condition. The most common are c.1516G>A (p.Arg506Gln) and c.1056C>T (p.Ser352Leu). Research suggests that having one of these mutations in a parent increases the likelihood of the condition in offspring. A common understanding of genetic predisposition allows for screening and genetic counseling to identify carriers and potential cases among newborns.
Risk factors for the development of this disease
The main risk factors for developing LCHAD deficiency include:
- Heredity: family history of LCHAD.
- Genetic mutations: mutations in the HADHA gene.
- Use of certain medications: Certain medications may worsen the disease in susceptible individuals.
- Conditions associated with nutritional deficiencies or metabolic disorders.
- Pregnancy: risks to the fetus if the mother has a disease.
Understanding these factors allows physicians to more effectively identify and prevent the development of symptoms in potential patients.
Diagnosis of this disease
Major symptoms of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency may include:
- Weakness and fatigue.
- Myalgia and cramps.
- Hypoglycemia.
- Developmental pathologies in childhood.
- Cardiac disorders including cardiomyopathy.
Laboratory tests are quite important for diagnosis. They can detect increased levels of long-chain acyl-CoA in the blood and urine. Radiological examinations may be needed to evaluate the functioning of the heart and other organs. Differential diagnosis allows to exclude other metabolic pathologies, such as deficiency of other fatty acid oxidation enzymes or mitochondrial myopathies.
Treatment
General treatment for LCHAD involves a high-carbohydrate, low-fat diet to minimize the accumulation of toxic metabolites. Pharmacological treatment may include the use of carnitine to form acylcarnitine and reduce the toxic load. Surgery is not usually required because the disease is not associated with anatomical abnormalities. Other approaches may include genetic therapy, but this is still in the research phase. It is important to provide support and education to parents or caregivers to help them manage the disease more effectively.
List of medications used to treat this disease
Among the drugs used to treat LCHAD deficiency are:
- Carbnitine
- Hypoglycemic drugs (if necessary)
- B vitamins
- Special formulas for feeding infants
These drugs help manage symptoms and reduce the risk of metabolic crises.
Disease monitoring
Management of patients with LCHAD deficiency includes regular visits to the doctor for evaluation, monitoring of enzyme activation levels, and dietary control. Prognosis depends on timely diagnosis and correct treatment, but advanced cases can lead to serious complications, including heart disease and critical metabolic breakdowns. Attention should also be paid to possible associated conditions, such as hypoglycemia and cardiomyopathy.
Age-related features of the disease
Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency can present at any age, but neonates and children are of particular concern. Symptoms in neonates may include severe hypoglycemia and extreme fatigue. Older children often present with myalgia and hypotension. Adults may experience a longer course of the disease and develop cardiovascular disease.
Questions and Answers
- How is LCHAD deficiency diagnosed? Diagnostics is based on the work of laboratory research methods, including measurement of AKI levels in blood and urine.
- What are the main symptoms of the disease? The main symptoms include weakness, pain in the muscles, hypotension, as well as heart disease and myocarditis.
- What treatment is recommended for this condition? The treatment includes the use of spyglass and the introduction of carnitine to reduce toxicity.
- Can patients with LCHAD have children? Yes, I don't think I can do genetic consultations and maintenance.
- What complications can arise from the disease? The injuries include heart problems, hypotension, and persistent myocardial infarction.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov notes that an important aspect in managing the disease is proper diet, especially in early childhood. “Regular consultations with neuro-metabolic specialists will help maintain the child’s health and avoid major metabolic crises. It is also important for parents to receive sufficient information about symptoms that may signal the need to seek medical help,” he adds. Proper medical support and active family participation in the treatment process are of great importance for improving the quality of life of patients.
